Skip to main content
Top
Published in: American Journal of Clinical Dermatology 12/2003

01-12-2003 | Current Opinion

Is Antibiotic Resistance in Cutaneous Propionibacteria Clinically Relevant?

Implications of Resistance for Acne Patients and Prescribers

Authors: Anne E. Eady, Dr Jonathan H. Cove, Alison M. Layton

Published in: American Journal of Clinical Dermatology | Issue 12/2003

Login to get access

Abstract

It is well recognized that some patients with acne do not respond adequately to antibiotic therapy. It is important to distinguish antibiotic recalcitrant acne which we would suggest represents acne that shows a diminished response to treatment irrespective of the cause as opposed to ‘antibiotic-resistant acne’ which is acne that is less responsive to treatment as a direct consequence of skin colonization with resistant propionibacteria. Here we show that antibiotic-resistant acne is not just a theoretical possibility but a real phenomenon that could have important consequences for patients and prescribers. The relationship between skin colonization by antibiotic-resistant propionibacteria and treatment outcomes is a complex one that is explained at the follicular level by physiological differences affecting local drug concentrations. A systematic review of the literature on antibiotic-resistant propionibacteria revealed methodological shortcomings in studies of their prevalence and a paucity of evidence on their clinical significance. Despite the elucidation of resistance mechanisms in cutaneous propionibacteria, our continuing inability to distinguish between strains of Propionibacterium acnes means that we still do not fully understand how resistance spreads, although person-to-person transfer is most likely. Finally, we present a decision tree for acne management in an era of prudent antimicrobial prescribing that provides an alternative to existing treatment algorithms by placing topical retinoids and not antibiotics at the cornerstone of acne management.
Footnotes
1
Although reductions in propionibacterial numbers at the skin surface are not large, topical clindamycin appears to be capable of sterilizing comedones in some patients.
 
Literature
1.
go back to reference Leyden JJ. The acne challenge: management in an age of antibiotic resistance [online]. CME Certified Monograph. Medical Crossfire 2002; 3. Available from URL: http://www.medicalcrossfire.com/debate_archive/2002/Special_Editions/acne.pdf [Accessed 2003 Sep 4] Leyden JJ. The acne challenge: management in an age of antibiotic resistance [online]. CME Certified Monograph. Medical Crossfire 2002; 3. Available from URL: http://​www.​medicalcrossfire​.​com/​debate_​archive/​2002/​Special_​Editions/​acne.​pdf [Accessed 2003 Sep 4]
3.
go back to reference Whiteside JA, Voss JG. Incidence and lipolytic activity of Propionibacterium acnes (Corynebacterium acnes group I) and P. granulosum (C. acnes group II) in acne and in normal skin. J Invest Dermatol 1973; 60: 94–7PubMedCrossRef Whiteside JA, Voss JG. Incidence and lipolytic activity of Propionibacterium acnes (Corynebacterium acnes group I) and P. granulosum (C. acnes group II) in acne and in normal skin. J Invest Dermatol 1973; 60: 94–7PubMedCrossRef
4.
go back to reference Marples RR, McGinley KJ, Mills OH. Microbiology of comedones in acne vulgaris. J Invest Dermatol 1973; 60: 80–3PubMedCrossRef Marples RR, McGinley KJ, Mills OH. Microbiology of comedones in acne vulgaris. J Invest Dermatol 1973; 60: 80–3PubMedCrossRef
5.
go back to reference Leyden JJ, McGinley KJ, Mills OH, et al. Propionibacterium levels in patients with and without acne vulgaris. J Invest Dermatol 1975; 65: 382–4PubMedCrossRef Leyden JJ, McGinley KJ, Mills OH, et al. Propionibacterium levels in patients with and without acne vulgaris. J Invest Dermatol 1975; 65: 382–4PubMedCrossRef
6.
go back to reference Golub LM, Lee HM, Ryan ME, et al. Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms. Adv Dent Res 1998; 12: 12–26PubMedCrossRef Golub LM, Lee HM, Ryan ME, et al. Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms. Adv Dent Res 1998; 12: 12–26PubMedCrossRef
7.
go back to reference Keicho N, Kudoh S, Yotsumoto H, et al. Antilymphocytic activity of erythromycin distinct from that of FK506 or cyclosporin A. J Antibiot (Tokyo) 1993; 46: 1406–13CrossRef Keicho N, Kudoh S, Yotsumoto H, et al. Antilymphocytic activity of erythromycin distinct from that of FK506 or cyclosporin A. J Antibiot (Tokyo) 1993; 46: 1406–13CrossRef
8.
go back to reference Viora M, de Luca A, D’Ambrosio A, et al. In vitro and in vivo immunomodulatory effects of anti-Pneumocystis carinii drugs. Antimicrob Agents Chemother 1996; 40: 1294–7PubMed Viora M, de Luca A, D’Ambrosio A, et al. In vitro and in vivo immunomodulatory effects of anti-Pneumocystis carinii drugs. Antimicrob Agents Chemother 1996; 40: 1294–7PubMed
9.
go back to reference Hand WL, Corwin RW, Steinberg TH, et al. Uptake of antibiotics by human alveolar macrophages. Am Rev Respir Dis 1984; 129: 933–7PubMed Hand WL, Corwin RW, Steinberg TH, et al. Uptake of antibiotics by human alveolar macrophages. Am Rev Respir Dis 1984; 129: 933–7PubMed
10.
go back to reference Murdoch MB, Peterson LR. Antimicrobial penetration into polymorphonuclear leucocytes and alveolar macrophages. Semin Respir Infect 1991; 6: 112–21PubMed Murdoch MB, Peterson LR. Antimicrobial penetration into polymorphonuclear leucocytes and alveolar macrophages. Semin Respir Infect 1991; 6: 112–21PubMed
11.
go back to reference Skidmore R, Kovach R, Walker C, et al. Effects of subantimicrobial-dose doxycycline in the treatment of moderate acne. Arch Dermatol 2003; 139: 459–64PubMedCrossRef Skidmore R, Kovach R, Walker C, et al. Effects of subantimicrobial-dose doxycycline in the treatment of moderate acne. Arch Dermatol 2003; 139: 459–64PubMedCrossRef
12.
go back to reference Ferguson J. Recent trends in the prescribing of antibiotics. Prescriber 2001; 12: 59–62 Ferguson J. Recent trends in the prescribing of antibiotics. Prescriber 2001; 12: 59–62
13.
go back to reference Martin WJ, Gardner M, Washington JA. In vitro antimicrobial susceptibility of anaerobic bacteria isolated from clinical specimens. Antimicrob Agents Chemother 1972; 1: 148–58PubMedCrossRef Martin WJ, Gardner M, Washington JA. In vitro antimicrobial susceptibility of anaerobic bacteria isolated from clinical specimens. Antimicrob Agents Chemother 1972; 1: 148–58PubMedCrossRef
14.
go back to reference Chow AW, Patten V, Guze LB. Comparative susceptibility of anaerobic bacteria to minocycline, doxycycline and tetracycline. Antimicrob Agents Chemother 1975; 7: 46–9PubMedCrossRef Chow AW, Patten V, Guze LB. Comparative susceptibility of anaerobic bacteria to minocycline, doxycycline and tetracycline. Antimicrob Agents Chemother 1975; 7: 46–9PubMedCrossRef
15.
go back to reference Guin JD, Huber DS, Gielerak PL. Antibiotic susceptibility of comedonal Propionibacterium acnes. Acta Derm Venereol 1979; 59: 552–4PubMed Guin JD, Huber DS, Gielerak PL. Antibiotic susceptibility of comedonal Propionibacterium acnes. Acta Derm Venereol 1979; 59: 552–4PubMed
16.
go back to reference Crawford WW, Crawford IP, Stoughton RB, et al. Laboratory induction and clinical occurence of combined clindamycin and erythromycin resistance in Corynebacterium acnes. J Invest Dermatol 1979; 72: 187–90PubMedCrossRef Crawford WW, Crawford IP, Stoughton RB, et al. Laboratory induction and clinical occurence of combined clindamycin and erythromycin resistance in Corynebacterium acnes. J Invest Dermatol 1979; 72: 187–90PubMedCrossRef
17.
go back to reference Cooper AJ. Systematic review of Propionibacterium acnes resistance to systemic antibiotics. Med J Aust 1998; 169: 259–61PubMed Cooper AJ. Systematic review of Propionibacterium acnes resistance to systemic antibiotics. Med J Aust 1998; 169: 259–61PubMed
18.
go back to reference Flühr JW, Gloor M, Dietz P, et al. In vitro activity of 6 antimicrobials against propionibacterial isolates from untreated acne papulopustulosa. Zentralbl Bakteriol 1999; 289: 53–61PubMedCrossRef Flühr JW, Gloor M, Dietz P, et al. In vitro activity of 6 antimicrobials against propionibacterial isolates from untreated acne papulopustulosa. Zentralbl Bakteriol 1999; 289: 53–61PubMedCrossRef
19.
go back to reference Dréno B, Reynaud A, Moyse D, et al. Erythromycin resistance of cutaneous bacterial flora in acne. Eur J Dermatol 2001; 11: 549–53PubMed Dréno B, Reynaud A, Moyse D, et al. Erythromycin resistance of cutaneous bacterial flora in acne. Eur J Dermatol 2001; 11: 549–53PubMed
20.
go back to reference Tan HH, Goh CKL, Yeo MGC, et al. Antibiotic susceptibility of Propionibacterium acnes isolates from patients with acne vulgaris in a tertiary dermatological referral centre in Singapore. Ann Acad Med Singapore 2001; 30: 22–5PubMed Tan HH, Goh CKL, Yeo MGC, et al. Antibiotic susceptibility of Propionibacterium acnes isolates from patients with acne vulgaris in a tertiary dermatological referral centre in Singapore. Ann Acad Med Singapore 2001; 30: 22–5PubMed
21.
go back to reference Ross JI, Snelling AM, Carnegie E, et al. Antibiotic resistant acne: lessons from Europe. Br J Dermatol 2003; 148: 467–78PubMedCrossRef Ross JI, Snelling AM, Carnegie E, et al. Antibiotic resistant acne: lessons from Europe. Br J Dermatol 2003; 148: 467–78PubMedCrossRef
22.
go back to reference Leyden JJ. Historical perspective on the emergence of propionibacterial resistance: current views on how to combat the problem [oral presentation]. Australasian College of Dermatologists Annual Meeting; 1998 May; Melbourne Leyden JJ. Historical perspective on the emergence of propionibacterial resistance: current views on how to combat the problem [oral presentation]. Australasian College of Dermatologists Annual Meeting; 1998 May; Melbourne
23.
go back to reference Coates P, Vyakrnam S, Eady EA, et al. Prevalence of antibiotic-resistant propionibacteria on the skin of acne patients: 10-year surveillance data and snapshot distribution study. Br J Dermatol 2002; 146: 840–8PubMedCrossRef Coates P, Vyakrnam S, Eady EA, et al. Prevalence of antibiotic-resistant propionibacteria on the skin of acne patients: 10-year surveillance data and snapshot distribution study. Br J Dermatol 2002; 146: 840–8PubMedCrossRef
24.
go back to reference Leyden JJ, McGinley KJ, Cavalieri S, et al. Propionibacterium acnes resistance to antibiotics in acne patients. J Am Acad Dermatol 1983; 8: 41–5PubMedCrossRef Leyden JJ, McGinley KJ, Cavalieri S, et al. Propionibacterium acnes resistance to antibiotics in acne patients. J Am Acad Dermatol 1983; 8: 41–5PubMedCrossRef
25.
go back to reference Leeming JP, Holland KT, Cunliffe WJ. The microbial ecology of inflamed acne vulgaris lesions. Br J Dermatol 1988; 118: 203–8PubMedCrossRef Leeming JP, Holland KT, Cunliffe WJ. The microbial ecology of inflamed acne vulgaris lesions. Br J Dermatol 1988; 118: 203–8PubMedCrossRef
26.
go back to reference Eady EA, Cove JH, Holland KT, et al. Erythromycin resistant propionibacteria in antibiotic treated acne patients: association with therapeutic failure. Br J Dermatol 1989; 121: 51–7PubMedCrossRef Eady EA, Cove JH, Holland KT, et al. Erythromycin resistant propionibacteria in antibiotic treated acne patients: association with therapeutic failure. Br J Dermatol 1989; 121: 51–7PubMedCrossRef
27.
go back to reference Ross JI, Eady EA, Carnegie E, et al. Detection of transposon Tn5432-mediated macrolide-lincosamide-streptogramin B (MLSB) resistance in cutaneous propionibacteria from six European cities. J Antimicrob Chemother 2002; 49: 165–8PubMedCrossRef Ross JI, Eady EA, Carnegie E, et al. Detection of transposon Tn5432-mediated macrolide-lincosamide-streptogramin B (MLSB) resistance in cutaneous propionibacteria from six European cities. J Antimicrob Chemother 2002; 49: 165–8PubMedCrossRef
28.
go back to reference Ozolins M, Eady EA, Avery A, et al. A randomised controlled multiple treatment comparison to provide a cost-effectiveness rationale for the selection of antimicrobial therapy in acne. NHS Health Technology Assessment Programme Monograph, 2003. In press (see URL http://www.ncchta.org/ProjectData/3_publication_listings_ALL.asp) Ozolins M, Eady EA, Avery A, et al. A randomised controlled multiple treatment comparison to provide a cost-effectiveness rationale for the selection of antimicrobial therapy in acne. NHS Health Technology Assessment Programme Monograph, 2003. In press (see URL http://​www.​ncchta.​org/​ProjectData/​3_​publication_​listings_​ALL.​asp)
29.
go back to reference Ross JI, Snelling AM, Eady EA, et al. Phenotypic and genotypic characterization of antibiotic-resistant Propionibacterium acnes isolated from acne patients attending dermatology clinics in Europe, the USA, Japan and Australia. Br J Dermatol 2001; 144: 339–46PubMedCrossRef Ross JI, Snelling AM, Eady EA, et al. Phenotypic and genotypic characterization of antibiotic-resistant Propionibacterium acnes isolated from acne patients attending dermatology clinics in Europe, the USA, Japan and Australia. Br J Dermatol 2001; 144: 339–46PubMedCrossRef
30.
go back to reference Frisk AR, Tunevall G. Clinical evaluation of minocycline. Antimicrob Agents Chemother 1968; 8: 335–9PubMed Frisk AR, Tunevall G. Clinical evaluation of minocycline. Antimicrob Agents Chemother 1968; 8: 335–9PubMed
31.
go back to reference MacDonald H, Kelly RG, Allen ES, et al. Pharmacokinetic studies of minocycline in man. Clin Pharmacol Ther 1973; 14: 852–61PubMed MacDonald H, Kelly RG, Allen ES, et al. Pharmacokinetic studies of minocycline in man. Clin Pharmacol Ther 1973; 14: 852–61PubMed
32.
go back to reference Sjölin-Forsberg G, Hermansson J. Comparative bioavailability of tetracycline and lymecycline. Br J Clin Pharmacol 1984; 18: 529–33PubMedCrossRef Sjölin-Forsberg G, Hermansson J. Comparative bioavailability of tetracycline and lymecycline. Br J Clin Pharmacol 1984; 18: 529–33PubMedCrossRef
33.
go back to reference Pascale D, Gordon J, Lamster I, et al. Concentration of doxycycline in human gingival fluid. J Clin Periodontol 1986; 13: 841–4PubMedCrossRef Pascale D, Gordon J, Lamster I, et al. Concentration of doxycycline in human gingival fluid. J Clin Periodontol 1986; 13: 841–4PubMedCrossRef
34.
go back to reference Gardner KJ, Eady EA, Cove JH, et al. Comparison of serum antibiotic levels in acne patients receiving the standard or a modified release formulation of minocycline hydrochloride. Clin Exp Dermatol 1997; 22: 72–6PubMedCrossRef Gardner KJ, Eady EA, Cove JH, et al. Comparison of serum antibiotic levels in acne patients receiving the standard or a modified release formulation of minocycline hydrochloride. Clin Exp Dermatol 1997; 22: 72–6PubMedCrossRef
35.
go back to reference Rashleigh PL, Rife E, Goltz RW. Tetracycline levels in skin surface film after oral administration of tetracycline to normal adults and to patients with acne vulgaris. J Invest Dermatol 1967; 49: 611–5PubMed Rashleigh PL, Rife E, Goltz RW. Tetracycline levels in skin surface film after oral administration of tetracycline to normal adults and to patients with acne vulgaris. J Invest Dermatol 1967; 49: 611–5PubMed
36.
go back to reference Aubin F, Blanc D, Guinchard C, et al. Absence of minocycline in sebum? J Dermatol 1989; 16: 369–73PubMed Aubin F, Blanc D, Guinchard C, et al. Absence of minocycline in sebum? J Dermatol 1989; 16: 369–73PubMed
37.
go back to reference Eady EA, Jones CE, Gardner KJ, et al. Tetracycline-resistant propionibacteria from acne patients are cross-resistant to doxycycline but sensitive to minocycline. Br J Dermatol 1993; 128: 556–60PubMedCrossRef Eady EA, Jones CE, Gardner KJ, et al. Tetracycline-resistant propionibacteria from acne patients are cross-resistant to doxycycline but sensitive to minocycline. Br J Dermatol 1993; 128: 556–60PubMedCrossRef
38.
go back to reference British National Formulary (BNF). Tetracyclines [online]. BNF 2003 Sep; vol. 46, s. 5.1.3 Available from URL: http://www.BNF.org [Accessed 2003 Oct 30] British National Formulary (BNF). Tetracyclines [online]. BNF 2003 Sep; vol. 46, s. 5.1.3 Available from URL: http://​www.​BNF.​org [Accessed 2003 Oct 30]
39.
go back to reference Bearden DT, Danziger LH. Mechanism of action and resistance to the quinolones. Pharmacotherapy 2001; 21: 224S-32SCrossRef Bearden DT, Danziger LH. Mechanism of action and resistance to the quinolones. Pharmacotherapy 2001; 21: 224S-32SCrossRef
40.
41.
go back to reference Guin JD, Lummis WL. Comedonal levels of free clindamycin following topical treatment with a 1% solution of clindamycin phosphate. J Am Acad Dermatol 1982; 7: 265–8PubMedCrossRef Guin JD, Lummis WL. Comedonal levels of free clindamycin following topical treatment with a 1% solution of clindamycin phosphate. J Am Acad Dermatol 1982; 7: 265–8PubMedCrossRef
42.
go back to reference Gardner KJ, Cunliffe WJ, Eady EA, et al. Variation in comedonal antibiotic concentrations following application of topical tetracycline for acne vulgaris. Br J Dermatol 1994; 131: 649–54PubMedCrossRef Gardner KJ, Cunliffe WJ, Eady EA, et al. Variation in comedonal antibiotic concentrations following application of topical tetracycline for acne vulgaris. Br J Dermatol 1994; 131: 649–54PubMedCrossRef
43.
go back to reference Leyden J, Kaidbey K, Levy SF. The combination formulation of clindamycin 1% plus benzoyl peroxide 5% versus 3 different formulations of topical clindamycin alone in the reduction of Propionibacterium acnes. Am J Clin Dermatol 2001; 2: 263–6PubMedCrossRef Leyden J, Kaidbey K, Levy SF. The combination formulation of clindamycin 1% plus benzoyl peroxide 5% versus 3 different formulations of topical clindamycin alone in the reduction of Propionibacterium acnes. Am J Clin Dermatol 2001; 2: 263–6PubMedCrossRef
44.
go back to reference Leyden J, Levy S. The development of resistance in Propionibacterium acnes. Cutis 2001; 67: 21–4PubMed Leyden J, Levy S. The development of resistance in Propionibacterium acnes. Cutis 2001; 67: 21–4PubMed
45.
go back to reference Cunliffe WJ, Holland KT, Bojar RA, et al. A randomized, double-blind comparison of a clindamycin phosphate/benzoyl peroxide gel formulation and a matching clindamycin gel with respect to microbiologic activity and clinical efficacy in the topical treatment of acne vulgaris. Clin Ther 2002; 24: 1117–33PubMedCrossRef Cunliffe WJ, Holland KT, Bojar RA, et al. A randomized, double-blind comparison of a clindamycin phosphate/benzoyl peroxide gel formulation and a matching clindamycin gel with respect to microbiologic activity and clinical efficacy in the topical treatment of acne vulgaris. Clin Ther 2002; 24: 1117–33PubMedCrossRef
46.
go back to reference Eady EA, Bojar RA, Jones CE, et al. The effects of acne treatment with a combination of benzoyl peroxide and erythromycin on skin carriage of erythromycin resistant propionibacteria. Br J Dermatol 1996; 134: 107–13PubMedCrossRef Eady EA, Bojar RA, Jones CE, et al. The effects of acne treatment with a combination of benzoyl peroxide and erythromycin on skin carriage of erythromycin resistant propionibacteria. Br J Dermatol 1996; 134: 107–13PubMedCrossRef
47.
go back to reference Bojar RA, Eady EA, Jones CE, et al. Inhibition of erythromycin-resistant propionibacteria on the skin of acne patients by topical erythromycin with and without zinc. Br J Dermatol 1994; 130: 329–36PubMedCrossRef Bojar RA, Eady EA, Jones CE, et al. Inhibition of erythromycin-resistant propionibacteria on the skin of acne patients by topical erythromycin with and without zinc. Br J Dermatol 1994; 130: 329–36PubMedCrossRef
48.
go back to reference Apraiz D, Quintanilla E. Estudio bacteriológico y resistencia bacteriana del Propionibacterium acnes en el acné vulgar. Rev Diag Biol 1988; 37: 63–6 Apraiz D, Quintanilla E. Estudio bacteriológico y resistencia bacteriana del Propionibacterium acnes en el acné vulgar. Rev Diag Biol 1988; 37: 63–6
49.
go back to reference Chalker DK, Shalita A, Smith JG, et al. A double-blind study of the effectiveness of a 3% erythromycin and 5% benzoyl peroxide formulation in the treatment of acne vulgaris. J Am Acad Dermatol 1983; 9: 933–6PubMedCrossRef Chalker DK, Shalita A, Smith JG, et al. A double-blind study of the effectiveness of a 3% erythromycin and 5% benzoyl peroxide formulation in the treatment of acne vulgaris. J Am Acad Dermatol 1983; 9: 933–6PubMedCrossRef
50.
go back to reference Leyden JJ, Hicjman JG, Jarratt MT, et al. The efficacy and safety of a combination benzoyl peroxide /clindamycin topical gel compared with benzoyl peroxide alone and a benzoyl peroxide/erythromycin combination product. J Cutan Med Surg 2001; 5: 37–42PubMed Leyden JJ, Hicjman JG, Jarratt MT, et al. The efficacy and safety of a combination benzoyl peroxide /clindamycin topical gel compared with benzoyl peroxide alone and a benzoyl peroxide/erythromycin combination product. J Cutan Med Surg 2001; 5: 37–42PubMed
51.
go back to reference Lookingbill DP, Chalker DK, Lindholm JS, et al. Treatment of acne with a combination clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and vehicle gel: combined results of two double-blind investigations. J Am Acad Dermatol 1997; 37: 590–5PubMedCrossRef Lookingbill DP, Chalker DK, Lindholm JS, et al. Treatment of acne with a combination clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and vehicle gel: combined results of two double-blind investigations. J Am Acad Dermatol 1997; 37: 590–5PubMedCrossRef
52.
go back to reference Eady EA, Farmery MR, Ross JI, et al. Effects of benzoyl peroxide and erythromycin alone and in combination against antibiotic-sensitive and resistant skin bacteria from acne patients. Br J Dermatol 1994; 131: 331–6PubMedCrossRef Eady EA, Farmery MR, Ross JI, et al. Effects of benzoyl peroxide and erythromycin alone and in combination against antibiotic-sensitive and resistant skin bacteria from acne patients. Br J Dermatol 1994; 131: 331–6PubMedCrossRef
53.
go back to reference Burkhardt CN, Specht K, Neckers D. Synergistic activity of benzoyl peroxide and erythromycin. Skin Pharmacol Appl Skin Physiol 2000; 13: 292–6 Burkhardt CN, Specht K, Neckers D. Synergistic activity of benzoyl peroxide and erythromycin. Skin Pharmacol Appl Skin Physiol 2000; 13: 292–6
54.
go back to reference Wyatt TD, Ferguson WP, Wilson TS, et al. Gentamicin resistant Staphylococcus aureus associated with the use of topical gentamicin. J Antimicrob Chemother 1977; 3: 213–7PubMedCrossRef Wyatt TD, Ferguson WP, Wilson TS, et al. Gentamicin resistant Staphylococcus aureus associated with the use of topical gentamicin. J Antimicrob Chemother 1977; 3: 213–7PubMedCrossRef
55.
go back to reference Eady EA, Ross JI, Cove JH, et al. The effects of oral erythromycin therapy for acne on the development of resistance in cutaneous staphylococci and propionibacteria. In: Marks R, Plewig G, editors. Acne and related disorders. London: Dunitz, 1989: 265–70 Eady EA, Ross JI, Cove JH, et al. The effects of oral erythromycin therapy for acne on the development of resistance in cutaneous staphylococci and propionibacteria. In: Marks R, Plewig G, editors. Acne and related disorders. London: Dunitz, 1989: 265–70
56.
go back to reference Bojar RA, Cunliffe WJ, Holland KT. The short-term treatment of acne vulgaris with benzoyl peroxide: effects on the surface and follicular cutaneous microflora. Br J Dermatol 1995; 132: 204–8PubMedCrossRef Bojar RA, Cunliffe WJ, Holland KT. The short-term treatment of acne vulgaris with benzoyl peroxide: effects on the surface and follicular cutaneous microflora. Br J Dermatol 1995; 132: 204–8PubMedCrossRef
57.
go back to reference King K, Jones DH, Daltrey DC, et al. A double-blind study of the effects of 13-cis-retinoic acid on acne, sebum excretion rate and microbial population. Br J Dermatol 1982; 107: 583–90PubMedCrossRef King K, Jones DH, Daltrey DC, et al. A double-blind study of the effects of 13-cis-retinoic acid on acne, sebum excretion rate and microbial population. Br J Dermatol 1982; 107: 583–90PubMedCrossRef
58.
go back to reference Farmery MR, Jones CE, Eady EA, et al. In vitro activity of azelaic acid, benzoyl peroxide and zinc acetate against antibiotic-resistant propionibacteria from acne patients. J Dermatol Treat 1994; 5: 63–5CrossRef Farmery MR, Jones CE, Eady EA, et al. In vitro activity of azelaic acid, benzoyl peroxide and zinc acetate against antibiotic-resistant propionibacteria from acne patients. J Dermatol Treat 1994; 5: 63–5CrossRef
59.
go back to reference Flühr JW, Bosch B, Gloor M, et al. In-vitro and in-vivo efficacy of zinc acetate against propionibacteria alone and in combination with erythromycin. Zentralbl Bakteriol 1999; 289: 445–56PubMedCrossRef Flühr JW, Bosch B, Gloor M, et al. In-vitro and in-vivo efficacy of zinc acetate against propionibacteria alone and in combination with erythromycin. Zentralbl Bakteriol 1999; 289: 445–56PubMedCrossRef
60.
go back to reference McGinley KJ, Webster GF, Leyden JJ. Regional variation of cutaneous propionibacteria. Appl Environ Microbiol 1978; 35: 62–6PubMed McGinley KJ, Webster GF, Leyden JJ. Regional variation of cutaneous propionibacteria. Appl Environ Microbiol 1978; 35: 62–6PubMed
61.
go back to reference Singer TR, Isenberg SJ, Apt L. Conjunctival anaerobic and aerobic bacterial flora in paediatric versus adult subjects. Br J Ophthalmol 1988; 72: 448–51PubMedCrossRef Singer TR, Isenberg SJ, Apt L. Conjunctival anaerobic and aerobic bacterial flora in paediatric versus adult subjects. Br J Ophthalmol 1988; 72: 448–51PubMedCrossRef
62.
go back to reference Gerstener GJ, Grunberger W, Boschitsch E, et al. Vaginal organisms in prepubertal children with and without vulvovaginitis: a vaginoscopic study. Arch Gynaecol 1982; 231: 247–52CrossRef Gerstener GJ, Grunberger W, Boschitsch E, et al. Vaginal organisms in prepubertal children with and without vulvovaginitis: a vaginoscopic study. Arch Gynaecol 1982; 231: 247–52CrossRef
63.
go back to reference Sutter VL. Anaerobes as normal oral flora. Rev Infect Dis 1984; 6 Suppl. 1: S62–6CrossRef Sutter VL. Anaerobes as normal oral flora. Rev Infect Dis 1984; 6 Suppl. 1: S62–6CrossRef
64.
go back to reference Macfarlane GT, Cummings JH, Allison C. Protein degradation by human intestinal bacteria. J Gen Microbiol 1986; 132: 1647–56PubMed Macfarlane GT, Cummings JH, Allison C. Protein degradation by human intestinal bacteria. J Gen Microbiol 1986; 132: 1647–56PubMed
65.
go back to reference Neubert U, Plewig G, Ruhfus A. Treatment of gram-negative folliculitis with isotretinoin. Arch Dermatol Res 1986; 278: 307–13PubMedCrossRef Neubert U, Plewig G, Ruhfus A. Treatment of gram-negative folliculitis with isotretinoin. Arch Dermatol Res 1986; 278: 307–13PubMedCrossRef
66.
go back to reference Lotem M, Ingber A, Filhaber A, et al. Skin infection provoked by coagulase-negative Staphylococcus resembling gram-negative folliculitis. Cutis 1988; 42: 443–4PubMed Lotem M, Ingber A, Filhaber A, et al. Skin infection provoked by coagulase-negative Staphylococcus resembling gram-negative folliculitis. Cutis 1988; 42: 443–4PubMed
67.
go back to reference Sturkenboom MC, Meier CR, Jick H, et al. Minocycline and lupuslike syndrome in acne patients. Arch Intern Med 1999; 159: 493–7PubMedCrossRef Sturkenboom MC, Meier CR, Jick H, et al. Minocycline and lupuslike syndrome in acne patients. Arch Intern Med 1999; 159: 493–7PubMedCrossRef
68.
go back to reference Shapiro LE, Knowles SR, Shear NH. Comparative safety of tetracycline, minocycline and doxycycline. Arch Dermatol 1997; 133: 1224–30PubMedCrossRef Shapiro LE, Knowles SR, Shear NH. Comparative safety of tetracycline, minocycline and doxycycline. Arch Dermatol 1997; 133: 1224–30PubMedCrossRef
69.
go back to reference Lawrenson RA, Seaman HE, Sundstrom A, et al. Liver damage associated with minocycline use in acne: a systematic review of the published literature and pharmacovigilance data. Drug Saf 2000; 23: 333–49PubMedCrossRef Lawrenson RA, Seaman HE, Sundstrom A, et al. Liver damage associated with minocycline use in acne: a systematic review of the published literature and pharmacovigilance data. Drug Saf 2000; 23: 333–49PubMedCrossRef
70.
go back to reference Eady EA, Ingham E. Propionibacterium acnes: friend or foe? Rev Med Microbiol 1994; 5: 163–73CrossRef Eady EA, Ingham E. Propionibacterium acnes: friend or foe? Rev Med Microbiol 1994; 5: 163–73CrossRef
71.
go back to reference Mills O, Thornsberry C, Cardin CW, et al. Bacterial resistance and therapeutic outcome following three months of topical acne therapy with 2% erythromycin gel versus its vehicle. Acta Dermatol Venereol 2002; 82: 260–5CrossRef Mills O, Thornsberry C, Cardin CW, et al. Bacterial resistance and therapeutic outcome following three months of topical acne therapy with 2% erythromycin gel versus its vehicle. Acta Dermatol Venereol 2002; 82: 260–5CrossRef
72.
go back to reference Eady EA, Holland KT, Cunliffe WJ. The use of antibiotics in acne therapy: oral or topical administration? J Antimicrob Chemother 1982; 10: 89–115PubMedCrossRef Eady EA, Holland KT, Cunliffe WJ. The use of antibiotics in acne therapy: oral or topical administration? J Antimicrob Chemother 1982; 10: 89–115PubMedCrossRef
73.
go back to reference Levy RM, Huang EY, Roling D, et al. Effect of antibiotics on the oropharyngeal flora in patients with acne. Arch Dermatol 2003; 139: 467–71PubMedCrossRef Levy RM, Huang EY, Roling D, et al. Effect of antibiotics on the oropharyngeal flora in patients with acne. Arch Dermatol 2003; 139: 467–71PubMedCrossRef
74.
go back to reference Layton AM, Cunliffe WJ, Eady EA. Cutaneous infections are not a significant feature of patients treated with topical clindamycin. J Dermatol Treat 1989; 1: 75–7CrossRef Layton AM, Cunliffe WJ, Eady EA. Cutaneous infections are not a significant feature of patients treated with topical clindamycin. J Dermatol Treat 1989; 1: 75–7CrossRef
75.
go back to reference Masio CM, Gutierrez RF. Antifungal drug resistance to azoles and polyenes. Lancet Infect Dis 2002; 2: 550–63CrossRef Masio CM, Gutierrez RF. Antifungal drug resistance to azoles and polyenes. Lancet Infect Dis 2002; 2: 550–63CrossRef
76.
go back to reference Eady EA, Ross JI, Cove JH, et al. Macrolide-lincosamide-streptogramin B (MLS) resistance in cutaneous propionibacteria: definition of phenotypes. J Antimicrob Chemother 1989; 23: 493–502PubMedCrossRef Eady EA, Ross JI, Cove JH, et al. Macrolide-lincosamide-streptogramin B (MLS) resistance in cutaneous propionibacteria: definition of phenotypes. J Antimicrob Chemother 1989; 23: 493–502PubMedCrossRef
77.
go back to reference National Institute of Clinical Excellence (NICE). Referral practice: a guide to appropriate referral from general to specialist services (version under pilot) [online]. NICE 2000 May: 15–17. Available from URL: http://www.nice.org.uk/pdf/NICE_GP_Referral_cues_4.pdf [Accessed 2003 Oct 30] National Institute of Clinical Excellence (NICE). Referral practice: a guide to appropriate referral from general to specialist services (version under pilot) [online]. NICE 2000 May: 15–17. Available from URL: http://​www.​nice.​org.​uk/​pdf/​NICE_​GP_​Referral_​cues_​4.​pdf [Accessed 2003 Oct 30]
78.
go back to reference Cunliffe WJ, van de Kerkhof PC, Caputo R, et al. Roaccutane treatment guidelines: results of an international survey. Dermatology 1997; 194: 351–7PubMedCrossRef Cunliffe WJ, van de Kerkhof PC, Caputo R, et al. Roaccutane treatment guidelines: results of an international survey. Dermatology 1997; 194: 351–7PubMedCrossRef
79.
go back to reference Lucky AW, Biro FM, Simbartl LA, et al. Predictors of severity of acne vulgaris in young adolescent girls: results of a five-year longitudinal study. J Paediatr 1997; 130: 30–9CrossRef Lucky AW, Biro FM, Simbartl LA, et al. Predictors of severity of acne vulgaris in young adolescent girls: results of a five-year longitudinal study. J Paediatr 1997; 130: 30–9CrossRef
80.
go back to reference Burke BM, Cunliffe WJ. The assessment of acne: the Leeds technique. Br J Dermatol 1984; 111: 83–92PubMedCrossRef Burke BM, Cunliffe WJ. The assessment of acne: the Leeds technique. Br J Dermatol 1984; 111: 83–92PubMedCrossRef
Metadata
Title
Is Antibiotic Resistance in Cutaneous Propionibacteria Clinically Relevant?
Implications of Resistance for Acne Patients and Prescribers
Authors
Anne E. Eady
Dr Jonathan H. Cove
Alison M. Layton
Publication date
01-12-2003
Publisher
Springer International Publishing
Published in
American Journal of Clinical Dermatology / Issue 12/2003
Print ISSN: 1175-0561
Electronic ISSN: 1179-1888
DOI
https://doi.org/10.2165/00128071-200304120-00002

Other articles of this Issue 12/2003

American Journal of Clinical Dermatology 12/2003 Go to the issue

Acknowledgments

Acknowledgment